Patients on haemodialysis (HD) and patients with type 2 diabetes are at highrisk for coronary artery calcification (CAC). The coronary artery calcium score (CACS), quantified by computed tomography, cannot be completely explained by traditional cardiovascular disease risk factors. CAC was measured in 45 non-diabetic chronic kidney disease patients on HD and in 45 matched type 2 diabetes patients without diabetic nephropathy. Serum calcium, phosphate, 25-hydroxyvitamin D (25[OH]D), alkaline phosphatase, intact parathyroid hormone (iPTH), fetuin-A, high-sensitivity C-reactive protein (hsCRP), albumin, homocysteine, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides and femoral neck bone mineral density were also measured. No differences were observed in patient distribution across the CACS risk categories between the two groups. Significant differences were observed in serum calcium, phosphate, 25(OH)D, alkaline phosphatase, iPTH, fetuin-A, hsCRP, homocysteine and triglycerides between the two patient groups. Further research into the diverse, numerous and often interlinked factors that influence CAC in different groups of patients is warranted.
Introduction
Cardiovascular disease (CVD), in particular coronary artery disease, is the leading cause of death in patients with type 2 diabetes and in chronic kidney disease (CKD) patients on haemodialysis (HD) in Western societies. 1,2 CVD in these patients can be attributed, at least in part, to traditional risk factors such as age, gender, lipids, arterial hypertension, smoking, diabetes and family history, but M Krajnc, B Pečovnik-Balon, R Hojs et al. Coronary artery calcification in kidney disease and type 2 diabetes the significantly higher prevalence and faster progression of CVD in these patients continue to be incompletely understood. 2 -4 Coronary artery calcification (CAC) is a vascular process that encompasses arterial intimal atherosclerosis and Monckeberg's medial calcific sclerosis. 3 -6 It can be effectively detected and quantified by electron-beam or multidetector computed tomography (EBCT/MDCT), most commonly by measuring total calcium. 5, 6 In the majority of studies, the extent of CAC is then expressed as the coronary artery calcium score (CACS). 6, 7 The extent of CAC has been shown to predict cardiovascular events and cardiovascular and all-cause mortality, independently of traditional risk factors and of established CVD risk stratification systems (e.g. Framingham). 6, 8 There are studies that suggest that measurement of CAC is an important index of risk in HD and type 2 diabetes patients. 4, 8 The published literature has highlighted a growing interest in identifying novel CVD risk factors that have not yet been fully elucidated. For example, some non-traditional risk factors for CAC appear to be related to bone metabolism (e.g. levels of serum calcium, phosphate, vitamin D, parathyroid hormone and alkaline phosphatase as markers of bone turnover, and bone mineral density [BMD]), especially in HD patients. 9 -13 The CAC process is thought to be tightly regulated and active. 9 -12 Calcification inhibitors that could be protective (e.g. fetuin-A) are of particular interest to researchers. 13 Inflammatory processes, reflected by elevated inflammation markers, such as C-reactive protein (CRP) and fibrinogen, also seem to contribute to CAC, 14 -16 as does homocysteine. 4 The difference in expression of these factors between the two groups of patients chosen for the present study (nondiabetic CKD patients on HD and matched type 2 diabetes patients without diabetic nephropathy) might help to explain some aspects of CAC.
Patients and methods

PATIENTS AND STUDY DESIGN
In this prospective study, adult CKD patients on HD and patients with established type 2 diabetes were enrolled sequentially between April 2007 and September 2010. Recruitment to the study was carried out randomly according to a computer generated schedule and the CKD patients on HD were matched to patients with established type 2 diabetes according to age and gender. All patients were free of known CVD. Patients with type 2 diabetes with certain or probable diabetic nephropathy and HD patients with diabetes mellitus were excluded from the study. In both groups, patients who were pregnant or had malignant disease were also excluded.
All patients were followed and treated at the University Medical Centre Maribor, Maribor, Slovenia in the Department of Haemodialysis, the Department of Endocrinology and Diabetology, and the Diabetes Out-patient Clinic. The study was approved by The Medical Ethics Commission of the Republic of Slovenia (Ljubljana, Slovenia). All patients gave their written informed consent to participate in the study.
CLINICAL MEASUREMENTS
Measurements, including CAC by MDCT using a 64-slice Toshiba Aquilion scanner (Toshiba, Tokyo, Japan), were made at baseline. Predefined analyses included an investigation of the association between categories and ranks of CAC for the two groups of patients. The CACS was calculated using the method of Agatston et al. 7 and comparison of the mean CACS for different CAC risk factors was carried out. One Blood samples were taken after an overnight fast using Vacutainer ® tubes (BD Biosciences, Plymouth, UK) according to the manufacturer's instruction. For serum determinations blood was collected into tubes with clot activator and gel for serum separation. Blood samples were analysed immediately after withdrawal. Serum calcium, phosphate, total cholesterol, lowdensity lipoprotein (LDL) cholesterol, highdensity lipoprotein (HDL) cholesterol, triglycerides, high-sensitivity CRP (hsCRP), fibrinogen, alkaline phosphatase, homocysteine and albumin were measured using standard laboratory tests. The hsCRP level was not included in the data analysis in the setting of bacterial infection or other apparent causes for its increase, but was reevaluated after resolution of such a cause. Fetuin-A was measured using a human fetuin-A enzyme-linked immunosorbent assay (BioVendor Research and Diagnostic Products, Brno, Czech Republic) and 25hydroxyvitamin D (25[OH]D) was measured by enzyme immunoassay (Immunodiagnostics Systems, Boldon, UK), according to the manufacturers' instructions. Levels of intact parathyroid hormone (iPTH) were measured using an Elecsys ® immunoassay system (Roche Diagnostics, Mannheim, Germany). Dual X-ray absorptiometry was used to measure absolute BMD (g/cm 2 ) of the femoral neck using a Hologic ® Explorer™ machine (Braintec, Ljubljana, Slovenia).
STATISTICAL ANALYSES
Statistical analyses were carried out using the SPSS ® statistical package, version 16.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Based on numerous previous publications, 5,8,17 -19 five categories of absolute CACS that correlate well with increasing risk of coronary events were used: 0, correlates with low risk; 1 -100, average risk; 101 -400, moderate risk; 401 -1000, high risk; and > 1000, very high risk. The χ 2 test was used to examine whether there was an association between a CAC category and either group of patients (CKD patients on HD versus type 2 diabetes patients). Wilcoxon's signed rank test was used to examine the difference between observations in the two groups.
Continuous variables were summarized as the mean ± SD. The CACS was summarized as the median and interquartile range because the data were not normally distributed. The means of the two groups were compared using 95% confidence intervals and a two-sided paired Student's t-test. A P-value < 0.05 was considered to be statistically significant and sufficient to reject the null hypothesis of no difference between the two groups.
Results
A total of 45 CKD patients on HD and 45 age-and gender-matched patients with type 2 diabetes were included in the study. Their demographic and clinical characteristics are shown in Table 1 . The type 2 diabetes patients had a significantly higher body mass index (BMI) compared with the CKD patients receiving HD (P < 0.05).
The median CACS in the CKD patients on HD was 155 (interquartile range 2 -1061; overall range 0 -8748) and, in the type 2 diabetes patients, the median CACS was 63 (interquartile range 6 -384; overall range 0 -3213). The distribution of patients across the CACS categories according to risk was not significantly different between the groups ( Table 2) .
Comparison of the selected risk factors for CAC between the two groups is presented in Table 3 . Significant differences were observed in serum calcium, phosphate, 25(OH)D, alkaline phosphatase, iPTH, fetuin-A, hsCRP,
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homocysteine and triglycerides between the two patient groups (P ≤ 0.03).
Discussion
The present study explored the difference in CACS and some proven and speculative risk factors for CAC between two distinct CVD high-risk groups, namely CKD patients on HD and type 2 diabetes patients. To our knowledge this is the first comparison of its kind to be published. The measurement of CAC by EBCT/MDCT has been the subject of extensive research not only because of its association with cardiovascular events and mortality, and its improvement of cardiovascular risk assessment, but also in order to investigate the natural history and pathogenesis of CAC and the impact of therapies on CAC. 6, 8, 19 It is also well known that HD patients and type 2 diabetes patients have a greater burden of certain CVD risk factors. 1, 2, 8 The median CACS, the range of CACS and maximum CACS in the present study were higher in HD patients than in type 2 diabetes patients, but the distribution of patients 22 found a median CACS of 41 in 71 asymptomatic type 2 diabetes patients. In the study by Raggi et al., 23 the median CACS was 565 (interquartile range 76 -1600) in 205 maintenance HD patients. Sigrist et al. 24 reported a prevalence of CAC of 46% in 46 predialysis patients compared with 70% in 60 HD patients. CAC was reported in approximately 60% of patients new to HD and in as many as 80 -85% of adult prevalent HD patients, 23 the latter being similar to the level seen in the present study. Becker et al. 25 found no coronary calcium in 15% of asymptomatic type 2 diabetes patients and CACS > 400 in 42%, which was not too dissimilar to the present study. The differences between the studies could be attributed to the methods used (EBCT versus MDCT) and to the different demographic characteristics and risk profiles of the patients. Age and gender distributions of CAC in the general population, detected by EBCT, have been published in the literature. 26 Type 2 diabetes patients have been shown to have a greater burden of obesity, lipid abnormalities (low HDL cholesterol, hypertriglyceridaemia, occasional high serum LDL cholesterol, elevated lipoprotein a, and related metabolic changes such as small dense LDL particles and enhanced oxidation of LDL), hyperinsulinaemia and the metabolic syndrome compared with nondiabetic patients, and these factors appear to be related to CACS, although not conclusively. 4, 27 -29 There was a significant difference in triglyceride levels between the two groups in the present study, but not in total cholesterol, LDL cholesterol or HDL cholesterol. This was probably as a consequence of the strict and effective dyslipidaemia control exerted by statins, particularly in the type 2 diabetes patients, and the fact that LDL cholesterol and total cholesterol are the primary targets of lipid control. 27, 30 As expected, type 2 diabetes patients were heavier than the CKD patients on HD, since obesity and adiposity are among the strongest risk factors for diabetes and less so for CKD. 31, 32 Hyperglycaemia and systemic and vessel wall inflammation also appear intertwined in accelerating vascular disease and CVD risk. 33 CRP is a well known marker of vascular inflammation and the presence of atherosclerosis. 34 The hsCRP levels in the present study were significantly higher in the type 2 diabetes patients compared with the CKD patients on HD. This could indicate that low-grade inflammation, as reflected by CRP, 35 was more pronounced in the type 2 diabetes patients. Based on a literature search of the PubMed database, there appears to be no reported data to indicate a correlation between calcium, phosphate, alkaline phosphatase and albumin in type 2 diabetes and CACS or vascular injury.
In HD patients, in addition to traditional risk factors, many new, diverse and also potentially interlinked factors have been recognized as important for CVD and CAC. Alterations in bone mineral metabolism appear to play a central role, particularly (elevated) plasma calcium and phosphate levels that correlate with mortality and vascular calcification, as does secondary hyperparathyroidism. 36, 37 These alterations were shown in the present study by significantly higher phosphate and iPTH levels in the CKD patients on HD compared with the type 2 diabetes patients. Calcium levels in the CKD patients on HD in the present study were significantly lower than in the type 2 diabetes patients, a fact that M Krajnc, B Pečovnik-Balon, R Hojs et al.
Coronary artery calcification in kidney disease and type 2 diabetes
can be attributed to stricter control of calcium levels with newer drugs and the implementation of explicit guidelines that calcium should be maintained within the normal range in CKD patients. 36 There is also evidence suggesting the importance of vitamin D, which commonly is very low in HD patients, for survival and cardiovascular risk, not only because of its suppression of parathyroid hormone, but also due to its numerous pleiotropic effects. 38 Additionally, there is emerging interest in the role of vitamin D in type 2 diabetes; it is thought to have immunomodulatory effects, and to influence inflammation and insulin sensitivity. 39 Based on target levels of > 75 nmol/l 40 the level of 25(OH)D was low in the CKD patients on HD in the present study but less so in the type 2 diabetes patients.
Calcification inhibitors, like fetuin-A, which is decreased in HD patients due to chronic inflammation and altered bone metabolism, contribute to vascular calcification and mortality. 13, 37 Ambiguous results exist on fetuin-A as a risk factor in vascular disease in type 2 diabetes and it has been found to be decreased in type 2 diabetes patients compared with non-diabetes patients. 13, 41 Fetuin-A was significantly lower in the CKD patients on HD than in the type 2 diabetes patients in the present study, suggesting the importance of bone mineral metabolism on the metabolism of fetuin-A.
Serum albumin is recognized as marker of body protein stores and several studies have demonstrated a negative correlation between albumin in HD patients and mortality, even at near normal levels. 42, 43 Interestingly, there was no difference in albumin levels between the two groups of patients in the present study, suggesting the protein status of the CKD patients on HD was favourable.
A meta-analysis by Heinz et al. 44 concluded that the level of homocysteine may be a risk factor for cardiovascular events and total mortality in patients with end-stage renal disease. Homocysteine is also a known risk factor for CACS in type 2 diabetes patients. 4,45 Significantly higher homocysteine levels were observed in the CKD patients on HD in the present study compared with the type 2 diabetes patients. This reflects the lower incidence of renal removal and the altered metabolism of homocysteine in CKD patients. 46 In HD patients, hip BMD is generally lower than normal reference ranges and, at this time, the utility of bone density measurements in HD patients remains uncertain and limited since they are also not correlated with histological type of bone disease. 47, 48 The association between diabetes mellitus and BMD remains controversial. The majority of studies have found that BMD is normal or increased in type 2 diabetes patients but, at the same time, their risk of fracture is higher. 49, 50 The present study showed no significant difference in femoral neck BMD between the two groups.
Serum alkaline phosphatase is a direct marker of bone turnover. It has been reported that, after adjusting for multiple known confounders, CKD patients with higher alkaline phosphatase levels had higher all-cause mortality. 48 The present study indicated significantly higher levels of alkaline phosphatase in the CKD patients on HD than in the type 2 diabetes patients, which could reflect more intensive bone turnover in the HD patients, a fact not unexpected when considering the incidence of bone mineral disorders in CKD. 36 In HD patients, there are still many uncertainties related to the possible role of different HD strategies, the effects of newer drugs (e.g. sevelamer, cinacalcet), the role of inflammation and treatment with statins on CAC. 51 -53 References Although the present study was small in size, it highlights the fact that the risk factors for CAC and CVD are numerous, diverse and, sometimes, different in distinct groups of patients, and that treatments can influence and modify these risk factors. The two groups of patients that were studied may be considered to have a similarly high risk for CAC and CVD (as correlated with CAC).
The results provide encouragement for moving to the next stage in terms of evaluating the similarities and dissimilarities that could contribute to an improved understanding of vascular disease.
